Form 4: Karyopharm Therapeutics CEO Richard Paulson Sells Shares to Cover Tax Obligations

Richard Paulson, CEO of Karyopharm Therapeutics, sold 4,099 shares of common stock at $0.65 per share to cover withholding tax liabilities.

Summary

• Richard A. Paulson, the President and CEO of Karyopharm Therapeutics Inc., sold 4,099 shares of common stock on February 4, 2025.
• The sale was executed at a price of $0.65 per share.
• This transaction was conducted under a pre-arranged automatic sale plan adopted on June 10, 2021.
• The purpose of the sale was to cover withholding tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Paulson directly owns 1,120,158 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (sale of shares for tax obligations) by the CEO, which is neither particularly positive nor negative. The pre-arranged sale plan mitigates concerns about insider trading.

Management Comments

• The sale does not represent a discretionary trade by the reporting person.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation, particularly when dealing with equity-based compensation.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, although the pre-arranged nature of the sale should mitigate any significant concerns.

Key Dates